These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30590609)

  • 21. ADARs and editing: The role of A-to-I RNA modification in cancer progression.
    Fritzell K; Xu LD; Lagergren J; Öhman M
    Semin Cell Dev Biol; 2018 Jul; 79():123-130. PubMed ID: 29146145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ADAR1, inosine and the immune sensing system: distinguishing self from non-self.
    Liddicoat BJ; Chalk AM; Walkley CR
    Wiley Interdiscip Rev RNA; 2016; 7(2):157-72. PubMed ID: 26692549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein kinase R and the integrated stress response drive immunopathology caused by mutations in the RNA deaminase ADAR1.
    Maurano M; Snyder JM; Connelly C; Henao-Mejia J; Sidrauski C; Stetson DB
    Immunity; 2021 Sep; 54(9):1948-1960.e5. PubMed ID: 34343497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ADAR RNA editing in innate immune response phasing, in circadian clocks and in sleep.
    Sinigaglia K; Wiatrek D; Khan A; Michalik D; Sambrani N; Sedmík J; Vukić D; O'Connell MA; Keegan LP
    Biochim Biophys Acta Gene Regul Mech; 2019 Mar; 1862(3):356-369. PubMed ID: 30391332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phenotypic Screen for Functional Mutants of Human Adenosine Deaminase Acting on RNA 1.
    Wang Y; Havel J; Beal PA
    ACS Chem Biol; 2015 Nov; 10(11):2512-9. PubMed ID: 26372505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccinia virus E3L interferon resistance protein inhibits the interferon-induced adenosine deaminase A-to-I editing activity.
    Liu Y; Wolff KC; Jacobs BL; Samuel CE
    Virology; 2001 Oct; 289(2):378-87. PubMed ID: 11689059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of ADAR1 through and beyond its editing activity in cancer.
    Jiao Y; Xu Y; Liu C; Miao R; Liu C; Wang Y; Liu J
    Cell Commun Signal; 2024 Jan; 22(1):42. PubMed ID: 38233935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ADAR RNA editing in human disease; more to it than meets the I.
    Gallo A; Vukic D; Michalík D; O'Connell MA; Keegan LP
    Hum Genet; 2017 Sep; 136(9):1265-1278. PubMed ID: 28913566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation.
    Stellos K; Gatsiou A; Stamatelopoulos K; Perisic Matic L; John D; Lunella FF; Jaé N; Rossbach O; Amrhein C; Sigala F; Boon RA; Fürtig B; Manavski Y; You X; Uchida S; Keller T; Boeckel JN; Franco-Cereceda A; Maegdefessel L; Chen W; Schwalbe H; Bindereif A; Eriksson P; Hedin U; Zeiher AM; Dimmeler S
    Nat Med; 2016 Oct; 22(10):1140-1150. PubMed ID: 27595325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of ADAR1-mediated modulation of gene expression.
    Gommans WM; Maas S
    Biochem Biophys Res Commun; 2008 Dec; 377(1):170-5. PubMed ID: 18835380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ADAR1-mediated RNA-editing of 3'UTRs in breast cancer.
    Sagredo EA; Blanco A; Sagredo AI; Pérez P; Sepúlveda-Hermosilla G; Morales F; Müller B; Verdugo R; Marcelain K; Harismendy O; Armisén R
    Biol Res; 2018 Oct; 51(1):36. PubMed ID: 30290838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dyschromatosis Symmetrica Hereditaria and Aicardi-Goutières Syndrome 6 Are Phenotypic Variants Caused by ADAR1 Mutations.
    Kono M; Matsumoto F; Suzuki Y; Suganuma M; Saitsu H; Ito Y; Fujiwara S; Moriwaki S; Matsumoto K; Matsumoto N; Tomita Y; Sugiura K; Akiyama M
    J Invest Dermatol; 2016 Apr; 136(4):875-878. PubMed ID: 26802932
    [No Abstract]   [Full Text] [Related]  

  • 33. Newly identified ADAR-mediated A-to-I editing positions as a tool for ALS research.
    Kwak S; Nishimoto Y; Yamashita T
    RNA Biol; 2008; 5(4):193-7. PubMed ID: 18971634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extensive editing of cellular and viral double-stranded RNA structures accounts for innate immunity suppression and the proviral activity of ADAR1p150.
    Pfaller CK; Donohue RC; Nersisyan S; Brodsky L; Cattaneo R
    PLoS Biol; 2018 Nov; 16(11):e2006577. PubMed ID: 30496178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein recoding by ADAR1-mediated RNA editing is not essential for normal development and homeostasis.
    Heraud-Farlow JE; Chalk AM; Linder SE; Li Q; Taylor S; White JM; Pang L; Liddicoat BJ; Gupte A; Li JB; Walkley CR
    Genome Biol; 2017 Sep; 18(1):166. PubMed ID: 28874170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bilateral striatal necrosis in two subjects with Aicardi-Goutières syndrome due to mutations in ADAR1 (AGS6).
    La Piana R; Uggetti C; Olivieri I; Tonduti D; Balottin U; Fazzi E; Orcesi S
    Am J Med Genet A; 2014 Mar; 164A(3):815-9. PubMed ID: 24376015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In cancer, A-to-I RNA editing can be the driver, the passenger, or the mechanic.
    Ganem NS; Ben-Asher N; Lamm AT
    Drug Resist Updat; 2017 May; 32():16-22. PubMed ID: 29145975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ADAR1-mediated 3' UTR editing and expression control of antiapoptosis genes fine-tunes cellular apoptosis response.
    Yang CC; Chen YT; Chang YF; Liu H; Kuo YP; Shih CT; Liao WC; Chen HW; Tsai WS; Tan BC
    Cell Death Dis; 2017 May; 8(5):e2833. PubMed ID: 28542129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phenolic small molecule inhibitor of RNase L prevents cell death from ADAR1 deficiency.
    Daou S; Talukdar M; Tang J; Dong B; Banerjee S; Li Y; Duffy NM; Ogunjimi AA; Gaughan C; Jha BK; Gish G; Tavernier N; Mao D; Weiss SR; Huang H; Silverman RH; Sicheri F
    Proc Natl Acad Sci U S A; 2020 Oct; 117(40):24802-24812. PubMed ID: 32958664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypic variation in Aicardi-Goutières syndrome explained by cell-specific IFN-stimulated gene response and cytokine release.
    Cuadrado E; Michailidou I; van Bodegraven EJ; Jansen MH; Sluijs JA; Geerts D; Couraud PO; De Filippis L; Vescovi AL; Kuijpers TW; Hol EM
    J Immunol; 2015 Apr; 194(8):3623-33. PubMed ID: 25769924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.